

**Biological Agents Controlled  
under the Import and Export Ordinance**

1C351 Human pathogens, zoonoses and "toxins", as follows :

(a) Viruses, whether natural, enhanced or modified, either in the form of "isolated live cultures" or as material including living material which has been deliberately inoculated or contaminated with such cultures, as follows :

- (1) Chikungunya virus;
- (2) Congo-Crimean haemorrhagic fever virus;
- (3) Dengue fever virus;
- (4) Eastern equine encephalitis virus;
- (5) Ebola virus;
- (6) Hantaan virus;
- (7) Junin virus;
- (8) Lassa fever virus;
- (9) Lymphocytic choriomeningitis virus;
- (10) Machupo virus;
- (11) Marburg virus;
- (12) Monkey pox virus;
- (13) Rift Valley fever virus;
- (14) Tick-borne encephalitis virus (Russian Spring-Summer encephalitis virus);
- (15) Variola virus;
- (16) Venezuelan equine encephalitis virus;
- (17) Western equine encephalitis virus;
- (18) White pox;
- (19) Yellow fever virus;
- (20) Japanese encephalitis virus;

(b) Rickettsiae, whether natural, enhanced or modified, either in the form of "isolated live cultures" or as material including living material which has been deliberately inoculated or contaminated with such cultures, as follows :

- (1) Coxiella burnetii;
- (2) Bartonella quintana (Rochalimaea quintana, Rickettsia quintana);
- (3) Rickettsia prowasecki;
- (4) Rickettsia rickettsii;

(c) Bacteria, whether natural, enhanced or modified, either in the form of "isolated live cultures" or as material including living material which has been deliberately inoculated or contaminated with such cultures, as follows :

- (1) Bacillus anthracis;
- (2) Brucella abortus;
- (3) Brucella melitensis;
- (4) Brucella suis;
- (5) Chlamydia psittaci;
- (6) Clostridium botulinum;
- (7) Francisella tularensis;
- (8) Burkholderia mallei (Pseudomonas mallei);
- (9) Burkholderia pseudomallei (Pseudomonas pseudomallei);

- (10) *Salmonella typhi*;
- (11) *Shigella dysenteriae*;
- (12) *Vibrio cholerae*;
- (13) *Yersinia pestis*;

(d) "Toxins", as follows, and "sub-units of toxins" thereof :

- (1) Botulinum toxins;  
Note :  
1C351(d)(1) does not control botulinum toxins in product form meeting all of the following criteria :
  - (1) Are pharmaceutical formulations designed for human administration in the treatment of medical conditions;
  - (2) Are pre-packaged for distribution as medical products;
  - (3) Are authorized by a state authority to be marketed as medical products.
- (2) *Clostridium perfringens* toxins;
- (3) Conotoxin;
- (4) Ricin;
- (5) Saxitoxin;
- (6) Shiga toxin;
- (7) *Staphylococcus aureus* toxins;
- (8) Tetrodotoxin;
- (9) Verotoxin;
- (10) Microcystin (Cyanginosin);
- (11) Aflatoxin;

except :

Any goods controlled by 1C351 in the form of a "vaccine" or immunotoxin".

1C352 Animal pathogens, as follows :

- (a) Viruses, whether natural, enhanced or modified, either in the form of "isolated live cultures" or as material including living material which has been deliberately inoculated or contaminated with such cultures, as follows :
  - (1) African swine fever virus
  - (2) Avian influenza virus, which are :
    - (a) Uncharacterised; or
    - (b) Defined in EC Directive 92/40/EC (O.J.L.16 23.1.92 p.19) as having high pathogenicity, as follows :
      - (i) Type A viruses with an IVPI (intravenous pathogenicity index) in 6 week old chickens of greater than 1.2; or
      - (ii) Type A viruses H5 or H7 subtype for which nucleotide sequencing has demonstrated multiple basic amino acids at the cleavage site of haemagglutinin;
  - (3) Bluetongue virus;
  - (4) Foot and mouth disease virus;
  - (5) Goat pox virus;
  - (6) Porcine herpes virus (Aujeszky's disease);
  - (7) Swine fever virus (Hog cholera virus);
  - (8) Lyssa virus;
  - (9) Newcastle disease virus;

- (10) Peste des petits ruminants virus;
- (11) Porcine enterovirus type 9 (swine vesicular disease virus);
- (12) Rinderpest virus;
- (13) Sheep pox virus;
- (14) Teschen disease virus;
- (15) Vesicular stomatitis virus;

- (b) *Mycoplasma mycoides*, whether natural, enhanced or modified, either in the form of "isolated live cultures" or as material including living material which has been deliberately inoculated or contaminated with such *Mycoplasma mycoides*;

except :

Any goods controlled by 1C352 in the form of a "vaccine".

1C353 Genetically-modified "microorganisms", as follows :

- (a) Genetically modified "microorganisms" or genetic elements that contain nucleic acid sequences associated with pathogenicity of organisms controlled by 1C351(a) to (c) or 1C352 or 1C354;
- (b) Genetically modified "microorganisms" or genetic elements that contain nucleic acid sequences coding for any of the "toxins" controlled by 1C351(d) or "sub-units of toxins" thereof;

1C354 Plant pathogens, as follows :

- (a) Bacteria; whether natural, enhanced or modified, either in the form of "isolated live cultures" or as material which has been deliberately inoculated or contaminated with such cultures, as follows :
  - (1) *Xanthomonas albilineans*;
  - (2) *Xanthomonas campestris* pv. *citri* including strains referred to as *Xanthomonas campestris* pv. *citri* types A, B, C, D, E or otherwise classified as *Xanthomonas citri*, *Xanthomonas campestris* pv. *aurantifolia* or *Xanthomonas campestris* pv. *citrumelo*;
- (b) Fungi, whether natural, enhanced or modified, either in the form of "isolated live cultures" or as material which has been deliberately inoculated or contaminated with such cultures, as follows :
  - (1) *Colletotrichum coffeanum* var. *virulans* (*Colletotrichum kahawae*);
  - (2) *Cochliobolus miyabeanus* (*Helminthosporium oryzae*);
  - (3) *Microcyclus ulei* (syn. *Dothidella ulei*);
  - (4) *Puccinia graminis* (syn. *Puccinia graminis* f. sp. *tritici*);
  - (5) *Puccinia striiformis* (syn. *Puccinia glumarum*);
  - (6) *Magnaporthe grisea* (*pyricularia grisea*/*pyricularia oryzae*);

Note : The products list is for reference only and may be subject to change from time to time. Traders are advised to refer to the schedules promulgated in the Import and Export (Strategic Commodities) Regulations (Cap. 60) for up-to-date information in relation to scope of products subject to licensing requirements.